Trans Genic Inc. AI Stock Analysis
Want to see JP:2342 full AI Analyst Report?
Trans Genic Inc. (2342) AI Stock Analysis
Trans Genic Inc.
(TSE/TYO:2342)
The overall score is low, primarily driven by weak cash flow generation and persistent negative free cash flow, which raises concerns about financial sustainability. This is compounded by a bearish technical picture with the stock in a clear downtrend and a very high P/E ratio that is not supported by current earnings or a dividend. A modestly stable balance sheet and signs of operational recovery prevent a lower score.
Trans Genic Inc. (2342) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.15B
- Dividend Yield
- ―
- Average Volume (3M)
- 48.05K
- Price to Earnings (P/E)
- -165.2
- Beta (1Y)
- 1.28
- Revenue Growth
- 8.53%
- EPS Growth
- 97.93%
- Country
- Japan
- Employees
- 227
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Trans Genic Inc. Business Overview & Revenue Model
Company Description
Trans Genic Inc., a Japanese enterprise, specializes in the development, distribution, and licensing of genetically engineered animals and antibodies. Its operations are structured into two primary divisions: Drug Discovery Support Business and Inves...
How the Company Makes Money
null
Trans Genic Inc. Financial Statement Overview
Summary
Financial performance is mixed. The income statement shows a recovery with a return to positive operating profit and narrowing net losses, but profitability remains inconsistent. The balance sheet is stable with manageable leverage (debt-to-equity of 0.44). However, cash flow is a significant concern, with persistent negative free cash flow and low operating cash flow coverage, indicating ongoing cash burn.
Income Statement
45NeutralBalance Sheet
55NeutralCash Flow
35Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.17B | 13.17B | 13.01B | 13.08B | 11.43B | 12.58B |
| Gross Profit | 2.43B | 2.43B | 2.17B | 2.25B | 1.99B | 3.84B |
| EBITDA | 293.56M | 293.56M | -64.37M | 253.62M | 158.37M | 2.07B |
| Net Income | -77.27M | -77.27M | -1.09B | 4.08M | -409.67M | 1.88B |
Balance Sheet | ||||||
| Total Assets | 9.74B | 9.74B | 9.59B | 9.84B | 10.68B | 10.44B |
| Cash, Cash Equivalents and Short-Term Investments | 2.13B | 2.13B | 2.56B | 2.48B | 3.46B | 4.62B |
| Total Debt | 2.09B | 2.09B | 2.58B | 2.26B | 2.43B | 1.86B |
| Total Liabilities | 4.90B | 4.90B | 4.73B | 3.84B | 4.56B | 3.80B |
| Stockholders Equity | 4.78B | 4.78B | 4.76B | 5.89B | 6.02B | 6.53B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -42.55M | -81.35M | -658.12M | -1.74B | 1.26B |
| Operating Cash Flow | 0 | 25.91M | 94.10M | -392.45M | -1.43B | 1.79B |
| Investing Cash Flow | 0 | 50.87M | -287.85M | -280.93M | -216.02M | 981.87M |
| Financing Cash Flow | 0 | -518.46M | 265.10M | -342.69M | 484.98M | -1.18B |
Trans Genic Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2342, the sentiment is Negative. The current price of 182.00 is below the 20-day moving average (MA) of 209.50, below the 50-day MA of 230.98, and below the 200-day MA of 248.91, indicating a bearish trend. The MACD of -8.29 indicates Positive momentum. The RSI at 33.22 is Neutral, neither overbought nor oversold. The STOCH value of 8.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2342.
Trans Genic Inc. Peers Comparison
Overall Rating
JP:619054Neutral
JP:488049Neutral
JP:234243Neutral
JP:497842Neutral
JP:777442Neutral
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 54Neutral | JPY 1.02B | -95.40 | ― | ― | -9.37% | 96.61% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | JPY 5.40B | 54.73 | ― | 1.84% | -9.94% | ― | |
| 43Neutral | JPY 3.07B | -165.15 | ― | ― | 8.53% | 97.93% | |
| 42Neutral | JPY 11.33B | -24.37 | ― | ― | -8.23% | -48.10% | |
| 42Neutral | JPY 26.32B | -73.22 | ― | ― | 17.05% | 10.47% | |
| 26Underperform | JPY 6.15B | -5.03 | ― | ― | -49.43% | -3.77% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2342 | Trans Genic Inc. | 182.00 | -44.00 | -19.47% | |
| JP:4880 | CellSource Co., Ltd. | 272.00 | -225.00 | -45.27% | |
| JP:4978 | ReproCELL Inc. | 106.00 | -52.00 | -32.91% | |
| JP:6190 | PhoenixBio Co., Ltd. | 249.00 | -157.00 | -38.67% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 648.00 | 170.00 | 35.56% | |
| JP:7776 | CellSeed Inc. | 155.00 | -225.00 | -59.21% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
